Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing
oleh: Maria Rivera, Haoran Zhang, Jessica Pham, Jane Isquith, Qingchen Jenny Zhou, Larisa Balaian, Roman Sasik, Sabina Enlund, Adam Mark, Wenxue Ma, Frida Holm, Kathleen M. Fisch, Dennis John Kuo, Catriona Jamieson, Qingfei Jiang
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-02-01 |
Deskripsi
Summary: Leukemia-initiating cells (LICs) are regarded as the origin of leukemia relapse and therapeutic resistance. Identifying direct stemness determinants that fuel LIC self-renewal is critical for developing targeted approaches. Here, we show that the RNA-editing enzyme ADAR1 is a crucial stemness factor that promotes LIC self-renewal by attenuating aberrant double-stranded RNA (dsRNA) sensing. Elevated adenosine-to-inosine editing is a common attribute of relapsed TÂ cell acute lymphoblastic leukemia (T-ALL) regardless of molecular subtype. Consequently, knockdown of ADAR1 severely inhibits LIC self-renewal capacity and prolongs survival in T-ALL patient-derived xenograft models. Mechanistically, ADAR1 directs hyper-editing of immunogenic dsRNA to avoid detection by the innate immune sensor melanoma differentiation-associated protein 5 (MDA5). Moreover, we uncover that the cell-intrinsic level of MDA5 dictates the dependency on the ADAR1-MDA5 axis in T-ALL. Collectively, our results show that ADAR1 functions as a self-renewal factor that limits the sensing of endogenous dsRNA. Thus, targeting ADAR1 presents an effective therapeutic strategy for eliminating T-ALL LICs.